128 related articles for article (PubMed ID: 12141739)
21. The recombinant outer surface protein A (lipOspA) of Borrelia burgdorferi: a Lyme disease vaccine.
Wallich R; Kramer MD; Simon MM
Infection; 1996; 24(5):396-7. PubMed ID: 8923055
[No Abstract] [Full Text] [Related]
22. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
Beran J; De Clercq N; Dieussaert I; Van Hoecke C
Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
[TBL] [Abstract][Full Text] [Related]
23. Availability of Lyme disease vaccine.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Jan; 48(2):35-6, 43. PubMed ID: 9933128
[TBL] [Abstract][Full Text] [Related]
24. Lyme disease vaccine safe for all?
Rahn DW
Postgrad Med; 1999 Jun; 105(7):21. PubMed ID: 10376044
[No Abstract] [Full Text] [Related]
25. Seroprevalence of Borrelia burgdorferi-specific C6 antibody in dogs before and after implementation of a nonadjuvanted recombinant outer surface protein A vaccine in a Rhode Island small animal clinic.
Hebert D; Eschner A
Vet Ther; 2010; 11(3):E1-9. PubMed ID: 20960414
[TBL] [Abstract][Full Text] [Related]
26. A recombinant vaccine for Lyme disease.
Wallich R; Kramer MD; Simon MM
Behring Inst Mitt; 1994 Dec; (95):106-8. PubMed ID: 7755503
[TBL] [Abstract][Full Text] [Related]
27. Lyme borreliosis in transgenic mice tolerant to Borrelia burgdorferi OspA or B.
Fikrig E; Tao H; Chen M; Barthold SW; Flavell RA
J Clin Invest; 1995 Oct; 96(4):1706-14. PubMed ID: 7560061
[TBL] [Abstract][Full Text] [Related]
28. Current understanding of Borrelia burgdorferi infection, with emphasis on its prevention in dogs.
Kazmierczak JJ; Sorhage FE
J Am Vet Med Assoc; 1993 Dec; 203(11):1524-8. PubMed ID: 8288471
[No Abstract] [Full Text] [Related]
29. Testing of the Biocan B inj. ad us. vet. vaccine and development of the new recombinant vaccine against canine borreliosis.
Tuhácková J; Bĕláková J; Krupka M; Neperený J; Chumela J; Weigl E; Vrzal V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):297-302. PubMed ID: 16601776
[TBL] [Abstract][Full Text] [Related]
30. Detection of Lyme disease after OspA vaccine.
Schutzer SE; Luan J; Coyle PK
N Engl J Med; 1997 Sep; 337(11):794-5. PubMed ID: 9289653
[No Abstract] [Full Text] [Related]
31. Importance of protective borreliacidal antibodies in Lyme disease immunity and serodiagnosis.
Callister SM; Schell RF
J Infect Dis; 1994 Aug; 170(2):499-500. PubMed ID: 8035047
[No Abstract] [Full Text] [Related]
32. Sera from patients with chronic Lyme disease protect mice from Lyme borreliosis.
Fikrig E; Bockenstedt LK; Barthold SW; Chen M; Tao H; Ali-Salaam P; Telford SR; Flavell RA
J Infect Dis; 1994 Mar; 169(3):568-74. PubMed ID: 8158028
[TBL] [Abstract][Full Text] [Related]
33. From the Food and Drug Administration.
Nightingale SL
JAMA; 1999 Feb; 281(5):408. PubMed ID: 9952188
[No Abstract] [Full Text] [Related]
34. Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis.
Hanson MS; Patel NK; Cassatt DR; Ulbrandt ND
Infect Immun; 2000 Nov; 68(11):6457-60. PubMed ID: 11035759
[TBL] [Abstract][Full Text] [Related]
35. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
Steere AC; Sikand VK; Meurice F; Parenti DL; Fikrig E; Schoen RT; Nowakowski J; Schmid CH; Laukamp S; Buscarino C; Krause DS
N Engl J Med; 1998 Jul; 339(4):209-15. PubMed ID: 9673298
[TBL] [Abstract][Full Text] [Related]
36. Characterization of a Borrelia burgdorferi VlsE invariable region useful in canine Lyme disease serodiagnosis by enzyme-linked immunosorbent assay.
Liang FT; Jacobson RH; Straubinger RK; Grooters A; Philipp MT
J Clin Microbiol; 2000 Nov; 38(11):4160-6. PubMed ID: 11060084
[TBL] [Abstract][Full Text] [Related]
37. Questions "push" for vaccination against Borrelia burgdorferi infection.
Greene RT
J Am Vet Med Assoc; 1992 Nov; 201(10):1491-3. PubMed ID: 1289318
[No Abstract] [Full Text] [Related]
38. Immunization of mice by recombinant OspA preparations and protection against Borrelia burgdorferi infection induced by Ixodes ricinus tick bites.
Gern L; Rais O; Capiau C; Hauser P; Lobet Y; Simoen E; Voet P; Pêtre J
Immunol Lett; 1994 Mar; 39(3):249-58. PubMed ID: 8034340
[TBL] [Abstract][Full Text] [Related]
39. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes.
Comstedt P; Schüler W; Meinke A; Lundberg U
PLoS One; 2017; 12(9):e0184357. PubMed ID: 28863166
[TBL] [Abstract][Full Text] [Related]
40. Lyme borreliosis: A neglected zoonosis in Egypt.
Elhelw RA; El-Enbaawy MI; Samir A
Acta Trop; 2014 Dec; 140():188-92. PubMed ID: 25239124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
